Notifiable trading – Equinor ASA
A close associate to a primary insider in Equinor ASA (OSE: EQNR, NYSE: EQNR) has sold shares in Equinor ASA.
Alf Torstensen, close associate to executive vice president Siv Helen Rygh Torstensen, has on 30 April 2024 sold 350 shares in Equinor ASA at a price of NOK 300.90 per share.
Details of the sale of shares are set forth in the attached notification.
This is information that Equinor ASA is obliged to make public pursuant to Article 19 of the EU Market Abuse Regulation and subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration21.5.2024 07:30:00 CEST | Press release
Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration Paris, New York, N.Y., and San Francisco, CA, May 21, 2024. Sanofi, Formation Bio and OpenAI are collaborating to build AI-powered software to accelerate drug development and bring new medicines to patients more efficiently. The three teams will bring together data, software and tuned models to develop custom, purpose-built solutions across the drug development lifecycle. This represents a first collaboration of its kind within the pharma and life sciences industries. Sanofi will leverage this partnership to provide access to proprietary data to develop AI models as it continues on its path to becoming the first biopharma company powered by AI at scale. Paul Hudson CEO, Sanofi “This unique collaboration is the next significant step in our journey to becoming a pharmaceutical company substantially powered by AI. Next generation, first-of-its kind AI model customizations will be an important foundation in our effor
FDA grants Breakthrough Therapy Designation to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation21.5.2024 07:00:00 CEST | Press release
The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting1Approximately 40% of people with HR-positive breast cancer have a PIK3CA mutation and often face poorer prognosis and resistance to endocrine treatment2,3 This is the 29th Breakthrough Therapy Designation for Roche’s oncology portfolio, a testament to our enduring ambition to deliver transformative medicines for patients4 Basel, 21 May 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for inavolisib, an investigational oral therapy, in combination with palbociclib (Ibrance®) and fulvestrant, for the treatment of adult patients with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer, following
DNO to Hold Fixed Income Investor Meetings21.5.2024 07:00:00 CEST | Press release
Oslo, 21 May 2024 – DNO ASA, the Norwegian oil and gas operator, today announced it has engaged DNB Markets, part of DNB Bank ASA, and Pareto Securities AS as Global Coordinators and Joint Bookrunners and with Arctic Securities AS as Joint Bookrunner to arrange fixed income investor meetings. Subject to inter alia market conditions and acceptable terms, a new senior unsecured bond issue with a tenor of five years may follow. The contemplated bond will materially have the same terms as DNO04, issued in September 2021. The purpose of the new bond issue is to partly refinance the DNO04 senior unsecured bonds with maturity in September 2026 (ISIN NO 0011088593) and for general corporate purposes. – For further information, please contact: Media: media@dno.no Investors: investor.relations@dno.no – DNO ASA is a Norwegian oil and gas operator active in the Middle East, the North Sea and West Africa. Founded in 1971 and listed on the Oslo Stock Exchange, the Company holds stakes in onshore and
Idorsia announces changes to Idorsia Executive Committee and Board of Directors21.5.2024 07:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Jean-Paul Clozel to retire as CEO and stand for election as Chairman of the Board of DirectorsMathieu Simon to stand for re-election to the Board – taking on the role of Vice-Chairman and Lead Independent DirectorAndré C. Muller, current CFO of Idorsia, to take over the role of CEO as of June 13, 2024 Allschwil, Switzerland – May 21, 2024 Idorsia Ltd (SIX: IDIA) today announced changes to the Idorsia Executive Committee (IEC) and will propose changes in membership of the Board of Directors at the upcoming Annual General Meeting of shareholders (AGM), to be held on June 13, 2024. Jean-Paul Clozel, 69, has decided to retire from his role as Chief Executive Officer (CEO) of Idorsia and stand for election as Chairman of the Board of Directors at this year’s AGM. Jean-Paul has served as CEO of Idorsia since its foundation – the result of demerging the drug discovery and early clinical pipeline of Actelion, as part of the USD 30 billion acquisition.
Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor21.5.2024 06:50:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – May 21, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first quarter of 2024. Business highlights Viatris collaboration: Global research and development collaboration, focused on the development and commercialization of two innovative compounds, selatogrel and cenerimod. Commercial highlights QUVIVIQ™ (daridorexant): Total net sales of CHF 10 million in Q1 2024.QUVIVIQ in the US: Citizens petition to deschedule the DORA class progressing.QUVIVIQ in Europe: Further launches, including France, provide a solid base to increase European sales in 2024. Pipeline highlights TRYVIO™ (aprocitentan): Approved by the US FDA in March 2024.JERAYGO™ (aprocitentan): Recommended for approval in Europe.Daridorexant: Phase 3 study conducted by Simcere in Chinese patients fully recruited. Financial highlights Net revenue Q1 2024 at CHF 10 million.US GAAP operating expenses Q1 2024 benefiting from extraordinary